Exploration of the guiding significance of protein regulating cytokinesis 1 in the management of gastrointestinal tumors

Abstract

Abstract: Objective: Analyzing the expression, biological role, and prognostic impact of protein regulating cytokinesis 1 (PRC1) in gastrointestinal tumors through bioinformatics tools, and subsequently guide clinical treatment.
Method: Based on a public database analysis, the expression level of PRC1 in gastrointestinal tumors, co-expressed genes, biological mechanisms of action, immunological regulatory characteristics, interpretation of gene mutation sites, prognostic impact on various tumors, and the prognostic impact of gene mutations on gastrointestinal tumors are analyzed.
Result: PRC1 was highly expressed in cholangiocarcinoma, colon cancer, liver cancer, pancreatic cancer, rectal cancer, and gastric cancer, and highly co-expressed with PRC1 related genes, which together affected the biological process of gastrointestinal tumors. The PRC1 and related gene sets were mainly enriched in mitotic related items in gene ontology (GO) enrichment analysis. In terms of immune promotion, PRC1 plays a regulatory role in B, CD4⁺, CD8⁺ and other immune cells in gastric and pancreatic cancer. PRC1 affects the biological process of gastrointestinal tumors in various forms of deep deletion, shallow deletion, diploid mutation, and amplification. The main mutation forms of each point on the PRC1 segment are missense mutations and truncations, which affect the translation and expression of PRC1, thereby affecting the biological process of gastrointestinal tumors. The high expression of PRC1 affects the prognosis of gastric cancer and pancreatic cancer. PRC1 mutation group indicates a poor prognosis of gastrointestinal tumors.
Conclusion: The high expression and mutation of PRC1 in gastrointestinal tumors are high-risk factors for malignant progression and poor prognosis of gastrointestinal tumors, further guiding clinical treatment strategies.

Key words: Protein regulating cytokinesis 1, Gastrointestinal tumor, Bioinformatic, Treatment

Liu Yifeng, Ran Yihong, Che Xu. Exploration of the guiding significance of protein regulating cytokinesis 1 in the management of gastrointestinal tumors[J]. Electronic Journal of Liver Tumor, 2024, 11(4): 27-35.

References

[1] CAO Y, HE H, LI R, et al.Latency-associated peptide identifies immunoevasive subtype gastric cancer with poor prognosis and inferior chemotherapeutic responsiveness[J]. Ann Surg, 2022, 275(1): e163-e173.
[2] WU D, ZHANG P, MA J, et al.Serum biomarker panels for the diagnosis of gastric cancer[J]. Cancer Med, 2019, 8(4): 1576-1583.
[3] PESSOA LS, HERINGER M, FERRER VP. ctDNA as a cancer biomarker: a broad overview[J]. Crit Rev Oncol Hematol, 2020, 155: 103109.
[4] LI J, DALLMAYER M, KIRCHNER T, et al.PRC1: linking cytokinesis, chromosomal instability, and cancer evolution[J]. Trends Cancer, 2018, 4(1): 59-73.
[5] VAN WIJNEN A J, BAGHERI L, BADRELDIN A A, et al. Biological functions of chromobox (CBX) proteins in stem cell self-renewal, lineage-commitment, cancer and development[J]. Bone, 2021, 143: 115659.
[6] HE Q, YANG J, JIN Y. Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma[J]. Brief Bioinform, 2022, 23(4): bbac291.
[7] TANG Z, LI C, KANG B, et al.GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-W102.
[8] WONG A K, PARK C Y, GREENE C S, et al.IMP: a multi-species functional genomics portal for integration, visualization and prediction of protein functions and networks[J]. Nucleic Acids Res, 2012, 40(Web Server issue): W484-W490.
[9] EVANGELISTA J E, XIE Z, MARINO G B, et al.Enrichr-KG: bridging enrichment analysis across multiple libraries[J]. Nucleic Acids Res, 2023, 51(W1): W168-W179.
[10] LI T, FAN J, WANG B, et al.TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer Res, 2017, 77(21): e108-e110.
[11] GAO J, AKSOY B A, DOGRUSOZ U, et al.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Sci Signal, 2013, 6(269): pl1.
[12] CAO T, PAN W, SUN X, et al.Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-a bioinformatics integrative analysis[J]. J Ovarian Res, 2019, 12(1): 101.
[13] ANTONOWICZ S, REDDY S, SGROMO B. Gastrointestinal side effects of upper gastrointestinal cancer surgery. Best practice & research[J]. Clin Gastroenterol, 2020, 48-49: 101706.
[14] VAN DIJK S M, HEERKENS H D, TSENG D S J, et al. Systematic review on the impact of pancreatoduodenectomy on quality of life in patients with pancreatic cancer[J]. HPB (Oxford), 2018, 20(3): 204-215.
[15] PATEL T H, CECCHINI M.Targeted therapies in advanced gastric cancer[J]. Curr Treat Options Oncol, 2020, 21(9): 70.
[16] ROLFO C, BRONTE G, SORTINO G, et al.The role of targeted therapy for gastrointestinal tumors[J]. Expert Rev Gastroenterol Hepatol, 2014, 8(8): 875-885.
[17] ERMAN M. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras[J]. J BUON, 2007, 12 Suppl 1: S83-S94.
[18] HAMADEH H K, TODD M, HEALY L, et al.Application of genomics for identification of systemic toxicity triggers associated with VEGF-R inhibitors[J]. Chem Res Toxicol, 2010, 23(6): 1025-1033.
[19] RENHOWE P A.Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical progress[J]. Curr Opin Drug Discov Devel, 2002, 5(2): 214-224.
[20] GIL J, O'LOGHLEN A. PRC1 complex diversity: where is it taking us?[J]. Trends Cell Biol, 2014, 24(11): 632-641.
[21] LI X H, JU J Q, PAN Z N, et al.PRC1 is a critical regulator for anaphase spindle midzone assembly and cytokinesis in mouse oocyte meiosis[J]. FEBS J, 2021, 288(9): 3055-3067.
[22] CHEN G, YU M, CAO J, et al.Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis[J]. Bioengineered, 2021, 12(1): 5149-5161.
[23] ZHANG H, ZHOU D, ZHU F, et al.Disordered APC/C-mediated cell cycle progression and IGF1/PI3K/AKT signalling are the potential basis of Sertoli cell-only syndrome[J]. Andrologia, 2019, 51(7): e13288.
[24] SCHERÜBL H. Type-2-diabetes and gastrointestinal cancer screening[J]. Z Gastroenterol, 2023, 61(6): 683-689.
[25] WOOD S L, PERNEMALM M, CROSBIE P A, et al.The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets[J]. Cancer Treat Rev, 2014, 40(4): 558-566.
[26] MAO X, XU J, WANG W, et al.Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives[J]. Mol Cancer, 2021, 20(1): 131.